Table 1. Clinicopathological characteristics and results of p53 immunostaining.
| UK patients (n=288) | Dutch patients (n=188) | All patients (n=476) | |
|---|---|---|---|
| Age (years) | |||
| Median | 58 | 59 | 59 |
| Range | 23–87 | 22–83 | 22–87 |
| PFS (months) | |||
| Median | 13 | 18 | 15 |
| Range | 0–135 | 0–158 | 0–158 |
| OS (months) | |||
| Median | 30 | 33 | 31 |
| Range | 0–136 | 37–186 | 0–186 |
| FIGO stage | |||
| Stage I | 21 (7.3%) | 23 (12.1%) | 44 (9.2%) |
| Stage II | 39 (13.5%) | 18 (9.6%) | 57 (12.0%) |
| Stage III | 181 (62.8%) | 117 (62.2%) | 298 (62.6%) |
| Stage IV | 47 (16.3%) | 29 (15.4%) | 76 (16.0%) |
| Missing | 0 | 1 (0.5%) | 1 (0.2%) |
| Tumour type | |||
| Serous | 154 (53.5%) | 105 (55.9%) | 259 (54.4%) |
| Mucinous | 14 (4.9%) | 15 (8.0%) | 29 (6.1%) |
| Clear cell | 15 (5.2%) | 13 (6.9%) | 28 (5.9%) |
| Endometrioid | 36 (12.5%) | 26 (13.8%) | 62 (13.0%) |
| Adenocarcinoma | 37 (12.8%) | 20 (10.6%) | 57 (12.0%) |
| Other | 30 (10.4%) | 9 (4.8%) | 39 (8.2%) |
| Missing | 2 (0.7%) | 0 | 2 (0.4%) |
| Tumour grade | |||
| Grade I | 19 (6.6%) | 23 (12.2%) | 47 (9.9%) |
| Grade II | 73 (25.3%) | 42 (22.3%) | 120 (25.2%) |
| Grade III | 158 (54.9%) | 96 (51.1%) | 256 (53.8%) |
| Missing | 38 (13.2%) | 27 (14.4%) | 53 (11.1%) |
| Residual disease | |||
| <2 cm | 140 (48.6%) | 65 (34.6%) | 207 (43.5%) |
| ⩾2 cm | 142 (49.3%) | 110 (58.5%) | 250 (52.5%) |
| Missing | 6 (2.1%) | 13 (6.9%) | 19 (4.0%) |
| Type of chemotherapy | |||
| Platinum containing | 98 (34.0%) | 95 (50.5%) | 195 (41.0%) |
| Platinum and taxane containing | 165 (57.3%) | 72 (38.3%) | 237 (49.8%) |
| Other regimen | 25 (8.7%) | 21 (11.2%) | 44 (9.2%) |
| P53 expression | |||
| Normal | 133 (46.2%) | 99 (52.7%) | 228 (47.9%) |
| Aberrant | 155 (53.8%) | 89 (47.3%) | 248 (52.1%) |
FIGO=International Federation of Gynaecology and Obstetrics; OS=overall survival; PFS=progression-free survival.